Info

Corcept Therapeutics Incorporated (Corcept) is a pharmaceutical company engaged in the development of drugs for the treatment of severe psychiatric and neurological diseases. The Company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Corcept's principal product candidate, CORLUX, modulates the effect of cortisol by selectively blocking the binding of cortisol to one of its two known receptors, the GR-II receptor, also known as the Type II or GR receptor. In June 2007, the Company announced preliminary results proof-of-concept clinical study evaluating the ability of CORLUX to mitigate weight gain associated with the use of Zyprexa (olanzapine), an antipsychotic medication. The Company has a license to the patent for the use of GR-II antagonists to treat the psychotic features of Pelizaeus-Merzbacher disease (PMD).(Source: 10-K)